Table 3.

Cox univariate regression for parameters of interest with respect to PFS and OS in the entire cohort and among patients with advanced non-small cell lung cancer

	OS			PFS
	Event/Total	HR (95% CI)	p value	Event/Total	HR (95% CI)	p value
Entire cohort
Immunomodulatory drug use (excluding corticosteroids)
No	24/92	Reference	–	55/92	Reference	–
Yes	6/31	0.79 (0.32–1.95)	0.616	17/31	1.06 (0.61–1.83)	0.844
Corticosteroid use
No	25/97	Reference	–	56/97	Reference	–
Yes	5/26	1.72 (0.64–4.62)	0.279	16/26	2.08 (1.18–3.68)	0.012
irAE
No	14/49	Reference	–	28/49	Reference	–
Yes	16/74	0.55 (0.27–1.12)	0.099	44/74	0.63 (0.39–1.02)	0.059

	OS			PFS
	Event/Total	HR (95% CI)	p value	Event/Total	HR (95% CI)	p value
Advanced NSCLC
Immunomodulatory drug use (excluding corticosteroids)
No	14/55	Reference	–	32/55	Reference	–
Yes	4/18	1.04 (0.34–3.18)	0.948	12/18	1.73 (0.88–3.38)	0.111
Corticosteroids use
No	14/56	Reference	–	32/56	Reference	–
Yes	4/17	2.11 (0.67–6.71)	0.204	12/17	2.78 (1.40–5.50)	0.003
irAE
No	5/24	Reference	–	14/24	Reference	–
Yes	13/49	0.65 (0.23–1.86)	0.425	30/49	0.48 (0.25–0.92)	0.026

CI confidence interval, HR hazard ratio, irAE immune-related adverse event, NSCLC non-small cell lung cancer, PFS progression-free survival, OS overall survival

Bold values indicate statistically significant parameters